Overview
A randomized Phase 1b/2, open-label, multi-center platform study to evaluate the efficacy of etrumadenant (AB928)-based combinations in patients with metastatic colorectal cancer.
Key Eligibility Criteria
- Histologically confirmed metastatic colorectal adenocarcinoma
- Inclusion Criteria for Cohort A:
- Disease progression following not more than one prior line of treatment for mCRC that consisted of oxaliplatin or irinotecan containing chemotherapy in combination with a biologic agent
- Inclusion Criteria for Cohort B:
- Disease progression during or following not more than two separate lines of treatment for mCRC that consisted of oxaliplatin, and irinotecan containing chemotherapy in combination with a biologic agent
- Inclusion Criteria for Cohort C:
- Disease progression during or following more than three separate lines of treatment for mCRC